Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 5
2021 3
2022 4
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Ballantyne CM, et al. Atherosclerosis. 2018 Oct;277:195-203. doi: 10.1016/j.atherosclerosis.2018.06.002. Epub 2018 Jun 12. Atherosclerosis. 2018. PMID: 29910030 Free article. Clinical Trial.
The primary endpoint was the percent change from baseline to week 12 in LDL-C. RESULTS: The study population comprised 269 patients (181 bempedoic acid, 88 placebo). Bempedoic acid added to background lipid-modifying therapy that included ezetimibe red …
The primary endpoint was the percent change from baseline to week 12 in LDL-C. RESULTS: The study population comprised 269 patients (181 …
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL. Ballantyne CM, et al. Eur J Prev Cardiol. 2020 Apr;27(6):593-603. doi: 10.1177/2047487319864671. Epub 2019 Jul 29. Eur J Prev Cardiol. 2020. PMID: 31357887 Free PMC article. Clinical Trial.
Patients were randomly assigned (2:2:2:1) to treatment with the fixed-dose combination, bempedoic acid 180 mg, ezetimibe 10 mg or placebo added to stable background statin therapy for 12 weeks. ...In this trial, fixed-dose combination treatment had a generally simil …
Patients were randomly assigned (2:2:2:1) to treatment with the fixed-dose combination, bempedoic acid 180 mg, ezetimibe 10 mg …
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Rubino J, et al. Atherosclerosis. 2021 Mar;320:122-128. doi: 10.1016/j.atherosclerosis.2020.12.023. Epub 2020 Dec 31. Atherosclerosis. 2021. PMID: 33514449 Clinical Trial.
This study evaluated LDL-C lowering with the combination of bempedoic acid, ezetimibe, and atorvastatin. METHODS: This was a phase 2, randomized, double-blind, placebo-controlled study (NCT03051100). After washout of lipid-lowering drugs, patients were randomized 2: …
This study evaluated LDL-C lowering with the combination of bempedoic acid, ezetimibe, and atorvastatin. METHODS: This was a p …
PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
Gunta SP, O'Keefe JH, O'Keefe EL, Lavie CJ. Gunta SP, et al. Prog Cardiovasc Dis. 2023 Jul-Aug;79:12-18. doi: 10.1016/j.pcad.2023.02.007. Epub 2023 Mar 5. Prog Cardiovasc Dis. 2023. PMID: 36871887 Review.
Yet, many people are intolerant of statins, whether due to true adverse events or the nocebo effect, so within one year about two-thirds of primary prevention patients and one-third of secondary prevention patients are no longer taking their prescription. ...Proprotein con …
Yet, many people are intolerant of statins, whether due to true adverse events or the nocebo effect, so within one year about two-thi …
New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia.
Pirillo A, Catapano AL. Pirillo A, et al. Curr Opin Endocrinol Diabetes Obes. 2022 Apr 1;29(2):161-166. doi: 10.1097/MED.0000000000000706. Curr Opin Endocrinol Diabetes Obes. 2022. PMID: 34980867 Free PMC article. Review.
A Mendelian randomization study has anticipated a protective cardiovascular effect of bempedoic acid; a randomized clinical trial is currently assessing whether the pharmacological control of hypercholesterolemia with bempedoic acid translates into a c …
A Mendelian randomization study has anticipated a protective cardiovascular effect of bempedoic acid; a randomized clinical tr …
Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials.
Bhagavathula AS, Al Matrooshi NO, Clark CCT, Rahmani J. Bhagavathula AS, et al. Clin Drug Investig. 2021 Jan;41(1):19-28. doi: 10.1007/s40261-020-00989-1. Epub 2020 Dec 23. Clin Drug Investig. 2021. PMID: 33368025
BACKGROUND AND OBJECTIVE: A limited number of trials have evaluated the efficacy of a fixed-dose combination of bempedoic acid and ezetimibe for the treatment of hypercholesterolemia. ...Regarding safety, bempedoic acid and ezetimibe combination was as …
BACKGROUND AND OBJECTIVE: A limited number of trials have evaluated the efficacy of a fixed-dose combination of bempedoic acid …
Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol.
Toth PP, Bray S, Villa G, Palagashvili T, Sattar N, Stroes ESG, Worth GM. Toth PP, et al. J Am Heart Assoc. 2022 Sep 20;11(18):e025551. doi: 10.1161/JAHA.122.025551. Epub 2022 Sep 8. J Am Heart Assoc. 2022. PMID: 36073669 Free PMC article.
At week 12, evolocumab, 140 mg every 2 weeks (Q2W)/420 mg once a month, and alirocumab, 150 mg Q2W, were the most efficacious regimens, followed by alirocumab, 75 mg Q2W, alirocumab, 300 mg once a month, inclisiran, bempedoic acid/ezetimibe fixed-dose combination, a …
At week 12, evolocumab, 140 mg every 2 weeks (Q2W)/420 mg once a month, and alirocumab, 150 mg Q2W, were the most efficacious regimens, foll …
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
Laufs U, Ballantyne CM, Banach M, Bays H, Catapano AL, Duell PB, Goldberg AC, Gotto AM, Leiter LA, Ray KK, Bloedon LT, MacDougall D, Zhang Y, Mancini GBJ. Laufs U, et al. J Clin Lipidol. 2022 May-Jun;16(3):286-297. doi: 10.1016/j.jacl.2022.03.001. Epub 2022 Mar 13. J Clin Lipidol. 2022. PMID: 35346603 Free article. Clinical Trial.
The fixed-dose combination of bempedoic acid with ezetimibe lowered LDL-C by 39.2% (95% CI, -51.7% to -26.7%; P<0.001). Muscle-related disorders occurred at a rate of 26.4 and 28.6 per 100 person-years with bempedoic acid and placebo, respectively. …
The fixed-dose combination of bempedoic acid with ezetimibe lowered LDL-C by 39.2% (95% CI, -51.7% to -26.7%; P<0.001). Mus …
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia.
Niman S, Rana K, Reid J, Sheikh-Ali M, Lewis T, Choksi RR, Goldfaden RF. Niman S, et al. Am J Cardiovasc Drugs. 2020 Dec;20(6):535-548. doi: 10.1007/s40256-020-00399-w. Am J Cardiovasc Drugs. 2020. PMID: 32166726 Review.
Furthermore, bempedoic acid is a prodrug that becomes activated by an enzyme expressed primarily in the liver, allowing it to avoid the potential myotoxicity associated with statin therapy. The purpose of this review is to summarize the major clinical studies evalua …
Furthermore, bempedoic acid is a prodrug that becomes activated by an enzyme expressed primarily in the liver, allowing it to …
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis.
Seijas-Amigo J, Cordero A, Olmo RF, Cortez Quiroga GA, Fácila L, Salgado-Barreira Á, Reyes-Santías F, Romero-Menor C, Murillo JR, Rodríguez-Mañero M, Bello Mora MC, Valle A, Sandin M, Pamias RF, Bañeras J, García PB, Lorenzo MC, Sánchez-Alvarez S, López-Rodríguez L, González-Juanatey JR. Seijas-Amigo J, et al. J Cardiovasc Pharmacol. 2023 Jan 1;81(1):70-75. doi: 10.1097/FJC.0000000000001365. J Cardiovasc Pharmacol. 2023. PMID: 36219195
Low-density lipoprotein cholesterol (LDLc) is the lead effector of atherosclerosis and main treatment target. Bempedoic acid is a novel oral drug in the therapeutic armamentarium which is able to reduce LDLc. The objectives of this study were (1) to select the poten …
Low-density lipoprotein cholesterol (LDLc) is the lead effector of atherosclerosis and main treatment target. Bempedoic acid i …
17 results